Overview
Binds to GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and release.
Proposed mechanism
Binds to albumin in the bloodstream via a Drug Affinity Complex (DAC) technology, extending the active half-life from minutes to days while continuously stimulating pituitary GH release.
What the evidence supports
Human data exists but the trials are small, short-term, or not yet replicated.
Graded Human-limited
Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
CJC-1295 pharmacokinetics
· DOI:10.1210/jc.2004-0981 · 2004
- [2]
GHRH analogs review
· DOI:10.1016/j.mce.2006.08.006 · 2006
- [3]
Jetté et al. — CJC-1295 pharmacokinetics and GH release in healthy adults
· · 0
- [4]
Alba et al. — Long-acting GHRH analogs and IGF-1
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.